DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.

DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.
复制标题

DOI:
10.1371/journal.pone.0067782
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Makrigiorgos GM
Makrigiorgos GM
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Guha M;Castellanos-Rizaldos E;Makrigiorgos GM

文献摘要

参考文献

被引文献

相似文献

使用小分子 EGFR 抑制剂(如吉非替尼)治疗的非小细胞肺癌 (NSCLC) 患者,由于存在继发突变(如 EGFR 外显子 20 上的 T790M 突变),经常会出现耐药性。这些突变可能源自原发肿瘤中的小亚克隆群体,这些亚克隆群体在治疗过程中后来成为主导。为了检测原发肿瘤中的这些低水平 DNA 变异或监测其在血浆中的进展,应用可靠且灵敏的突变检测方法非常重要。在这里,我们将两种最近开发的方法相结合,即临界温度下的差异链分离 (DISSECT) 和肽核酸锁核酸 (PNA-LNA) 聚合酶链反应 (PCR),用于检测 T790M EGFR 突变。在实施 PNA-LNA PCR 之前,DISSECT 从目标 DNA 中预富集低丰度 T790M EGFR 突变,这种方法可以在 100-1000 个野生型等位基因背景中检测 1 个突变等位基因。 DISSECT 和 PNA-LNA PCR 的组合能够在 10,000 个野生型等位基因的背景中检测 1 个突变等位基因。组合的 DISSECT-PNA-LNA PCR 方法适合灵敏检测癌症中其他新出现的耐药突变。
Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20. These mutations may originate from small subclonal populations in the primary tumor that become dominant later on during treatment. In order to detect these low-level DNA variations in the primary tumor or to monitor their progress in plasma, it is important to apply reliable and sensitive mutation detection methods. Here, we combine two recently developed methodologies, Differential Strand Separation at Critical Temperature (DISSECT), with peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) for the detection of T790M EGFR mutation. DISSECT pre-enriches low-abundance T790M EGFR mutations from target DNA prior to implementing PNA-LNA PCR, a method that can detect 1 mutant allele in a background of 100–1000 wild type alleles. The combination of DISSECT and PNA-LNA PCR enables the detection of 1 mutant allele in a background of 10,000 wild type alleles. The combined DISSECT-PNA-LNA PCR methodology is amenable to adaptation for the sensitive detection of additional emerging resistance mutations in cancer.
DOI: 10.1002/humu.21112
发表时间: 2009-11
期刊: HUMAN MUTATION
影响因子: 3.9
作者:
Li, Jin;Milbury, Coren A.;Li, Cheng;Makrigiorgos, G. Mike
通讯作者: Makrigiorgos, G. Mike
DOI: 10.1373/clinchem.2008.113035
发表时间: 2009-04
期刊: Clinical chemistry
影响因子: 9.3
作者:
Milbury CA;Li J;Makrigiorgos GM
通讯作者: Makrigiorgos GM
DOI: 10.1093/nar/gkm809
发表时间: 2007
影响因子: 14.9
作者:
Amicarelli G;Shehi E;Makrigiorgos GM;Adlerstein D
通讯作者: Adlerstein D
DOI: 10.1158/0008-5472.can-05-0331
发表时间: 2005-08-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Nagai, Y;Miyazawa, H;Hagiwara, K
通讯作者: Hagiwara, K
DOI: 10.1056/nejmoa044238
发表时间: 2005-02-24
影响因子: 158.5
作者:
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者: Halmos, B